Skip to main content

Table 3 Comparison of mfERG parameters (P1) at the baseline and final examination (6th month)

From: Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Ring

P1 amplitude (nv/deg2)

P1 implict time (ms)

Baseline

Final

P value

%95 CI (L, U)

Baseline

Final

P value

95% CI (L, U)

X ± SD

X ± SD

X ± SD

X ± SD

1

24,77 ± 17,87

39,77 ± 21,19

0,01*

(−21,61,-8,38)

44,17 ± 10,91

32,36 ± 10,22

0,01*

(−21,61,-8,38)

2

6,78 ± 4,3

13,62 ± 9,09

0,01*

(−10,02,-3,65)

45,17 ± 8,47

33,22 ± 9,84

0,02*

(−10,02,-3,65)

3

3,11 ± 3,86

5,68 ± 4,89

0,02*

(−3,76,-1,38)

41,99 ± 10,77

32,4 ± 11,47

0,01*

(−3,76,-1,38)

4

2,03 ± 1,37

2,74 ± 2,79

0,11

(−1,6,0,17)

47,31 ± 6,22

47,31 ± 6,22

0,26

(−1,6,0,17)

5

1,06 ± 0,84

1,13 ± 1,23

0,66

(−0,38,0,24)

48,49 ± 6,14

48,37 ± 6,68

0,47

(−0,38,0,24)

  1. X, mean values obtained from 34 eyes (32 patients); SD standard deviation;
  2. %95 CI L and U, 95% confidence interval of the difference (mean)
  3. * Bold: Significant p values and related data (i.e., coefficient and standard error) are set in italics
Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512